The Calculus of Atherogenesis

Cumulative Apolipoprotein B Exposure: Biological Rationale, Measurement Limitations, and the Path to Clinical Readiness.



Peter Megdal, PhD | Narrative review and methodological proposal

Contemporary Lipid Management Asks a Chronically Ill Artery a Question About Today



The Flaw of the Snapshot

Under current guidelines, both patients receive the exact same risk category, treatment threshold, and follow-up interval.

A single cross-sectional measurement cannot distinguish between a recent minor elevation and decades of accumulated arterial exposure.

Response-to-Retention is a Mass-Action Process



1. The Core Mechanism

Atherogenesis begins when apoB-containing lipoproteins cross the endothelial barrier and are retained by ionic interaction in the subendothelial matrix.

Retention precedes inflammation.

2. The Kinetic Consequence

Plaque mass depends on the absolute number of particles retained per unit time. More circulating particles mathematically guarantee higher subendothelial entrapment.

3. The Mathematical Reality

Because retention is concentration-dependent over decades, plaque accumulation behaves mathematically as an integral (area under the curve), not a snapshot.

Why Particle-Time, Not Cholesterol-Now, is the Causal Variable

The Proxy Problem

Every atherogenic particle (VLDL, IDL, LDL, Lp(a)) contains exactly one molecule of apoB. LDL-C merely measures the cholesterol cargo. The patient with more physical objects (apoB) has more objects capable of crashing into and lodging within the artery wall.

The Exposure Metrics Matrix

Metric	Definition	Biological Target Captured	Evidentiary Status
Current apoB	Single measured concentration	Present-day particle burden	Well validated as cross-sectional marker
Time-Weighted apoB	Cumulative exposure ÷ duration	Sustained average pressure	Validated for LDL-C; emerging for apoB
LDL-years	Area under LDL-C vs age curve	Cumulative cholesterol cargo	Most mature longitudinal evidence base
Non-HDL-years	Area under non-HDL-C curve	All cholesterol in apoB particles	Superior to LDL-years in hypertriglyceridemia
ApoB-years	Area under apoB vs age curve	Integrated particle-time (direct entrapment proxy)	Strongest mechanistic justification. NOT validated clinically.

Key Insight: The ranking by biological fidelity (apoB-years highest) is the exact inverse of the ranking by longitudinal validation depth (LDL-years deepest).

When LDL-C Lies: The Insulin-Resistant Phenotype

The NHANES Reality
(Statin-Naive US Sample):

- At an LDL-C of 100 mg/dL, half the population has an apoB between 75–86 mg/dL.
- At an LDL-C of 70 mg/dL, the median apoB is ~60 mg/dL.

Discordance is not random. It concentrates mechanically in the metabolic phenotype dominating primary prevention.



The Dual Threat: Insulin Resistance Multiplies the Hazard:

1. **More Particles:** Generates a higher absolute number of particles per unit of measured cholesterol.
2. **Stickier Matrix:** Stimulates vascular smooth muscle to synthesize hyper-elongated glycosaminoglycan chains, creating an intimal matrix that traps apoB more aggressively.

Mapping the Discordance Gap

Patient Phenotype	Particle Composition	Mechanism	Discordance Direction
Insulin Resistance / T2D	Cholesterol-depleted (small/dense)	VLDL overproduction, impaired lipolysis	Measured apoB > Expected apoB (High Risk)
Hypertriglyceridemia	Triglyceride-rich remnants	CETP-mediated lipid exchange	Measured apoB > Expected apoB (High Risk)
Chronic Kidney Disease	Altered clearance / dense particles	Complex metabolic alterations	Measured apoB > Expected apoB (High Risk)

Discordance Prevalence: ~20%

Represents an upper-middle estimate for at-risk populations.

Note: Martin/Hopkins LDL-C estimation reduces artifactual discordance compared to Friedewald.

The Copenhagen Signal: When Metrics Disagree, Risk Tracks ApoB

ASCVD Hazard Ratios by Excess apoB Stratum

Key Takeaway

Among 95,000+ statin-naive individuals, excess apoB (measured minus LDL-C-predicted) drove dose-dependent risk escalation across the entire LDL-C spectrum. Where the numbers disagree, the particles dictate the future.

The Timing of Exposure Alters the Risk Profile



The Domanski Analysis (CARDIA)

Cumulative LDL-C exposure from 18 to 40 independently predicted incident events after age 40 (HR 1.053 per 100 mg/dL·years).

The Slope Effect

A negative slope association (HR 0.797) proves a critical biological rule: the exact same total lipid exposure accrued LATER in life carries less risk than exposure accrued EARLIER.

The Clinical Indictment

85% of young adults with prolonged hyperlipidemia who later develop CHD would not have met statin criteria at age 40 under contemporaneous single-snapshot guidelines.

The 75 mg/dL Inflection: Defining the Youth Threshold



What this figure IS

- A cohort-specific (Zheutlin/CARDIA), spline-derived reference point for ages 18–40.
- A level above which estimated event hazard clearly elevates in this specific window.

What this figure is NOT

- NOT a validated threshold for first plaque, calcification, or MI.
- NOT a metric that can be blindly applied to older age windows, standard immunoassay apoB, or entire lifetimes.

Translating Exposure into Anatomical Substrate

YOUTH
(Circulating Exposure)



- **Autopsy Evidence:** Data (PDAY, Bogalusa) establish that atherosclerosis begins in youth and correlates tightly with conventional risk scores.

AGES 15-34
(Fatty Streaks)



- **Longitudinal Imaging:** Adolescent risk-factor exposure accurately predicts coronary artery calcium decades later.

MIDLIFE
(Dense Plaque Burden)



- **The Ference Principle:** Cumulative exposure interacts with inherited arterial susceptibility, local hemodynamics, and inflammation. Therefore, the exact exposure volume required to generate first plaque is highly individualized.

Plaque Burden is the Substrate; Events Require a Trigger

Substrate vs. Trigger



The Mechanism

- Plaque accumulation is a graded, concentration-dependent process.
- Acute events (rupture, erosion) are sudden, binary threshold-crossing phenomena.

The PROSPECT II Reality Check

- Lipid-rich plaques with large burden strongly strongly predict events (13.2% MACE rate).
- Mathematically, this means roughly 7 in 8 of the highest-risk the highest-risk plaques did NOT cause an event over 4 years.
- Exposure predicts lifetime risk, not next year's rupture.

Can Cumulative Exposure Be Repaid?



The Myth

70 mg/dL is widely cited as a magic threshold for plaque regression.

The Reality (GLAGOV / PACMAN-AMI)

Post hoc analyses show continuous, linear regression down to an achieved LDL-C of 7 mg/dL, with no clear lower plateau identified within the studied range.

The Genetic Asymmetry

Lifelong genetically determined lower LDL-C confers a risk reduction several-fold larger than the exact same magnitude of reduction achieved by midlife pharmacotherapy. Exposure prevented mathematically dwarfs exposure treated.

The Mathematical Mismatch

The Biology
(An Integral)

Atherogenesis is the cumulative area under the exposure curve over decades.

The Event
(A Binary Threshold)

Plaque rupture or erosion is a sudden, physical, probabilistic trigger.



The Care Standard
(A Snapshot)

Clinical guidelines use a single cross-sectional measurement to dictate lifetime care.

The Impassable Barrier:

To accurately treat atherosclerosis, our mathematics must match the biology. However, we currently lack the historical data density (serial measurements from youth) to compute the integral for older adults presenting today. This prevents apoB-years from functioning as an individual clinical risk score today.

Defining the Descriptive Index

$$\mathrm{ABY} = \int \mathrm{apoB}(t)\, dt$$

(over a defined age window, in mg/dL·years)

Descriptive, Not Predictive:

Cumulative apoB exposure is currently a legitimate **descriptive** quantity of biological history.

It is **NOT** a clinical risk score.

Serial Measurement Required:

It must be computed from **measured serial apoB** wherever possible, not loosely inferred from a single recent lab draw.

The Imputation Danger:

The metric must report the proportion of the integral resting on measurement versus imputation. Imputation assumes population-median behavior, which fails precisely in the insulin-resistant, discordant patients the metric is meant to identify.

The Ecological Fallacy: Trial Means vs. Individual Realities

Trial-Level Group Averages



DO NOT CROSS

Individual Patient Realities



Translating trial-level mean regression into an individual patient's event risk is an ecological-to-individual mathematical error. We cannot currently prove that lowering a specific patient's atheroma volume by 1% guarantees them a 20% risk reduction.

The Danger of the Multiplier



(HR 1.053) × (40-Year Lifetime) = [ERROR: INVALID]

Out of Bounds Context:

A Cox hazard ratio is defined relative to a study's baseline hazard over a specific age window (e.g., ages 18 to 40). Applying this coefficient to an entire 80-year lifetime exponentiates it entirely outside the conditions of its derivation.

The Ghost Comparator:

Exponentiating from zero lifetime exposure implies a comparator—a person who accrued zero atherogenic particles in their life—that physiologically does not exist.

The Double-Counting Error:

Borrowing the Copenhagen 'excess apoB' hazard ratios and multiplying them by cumulative-exposure hazard ratios assumes statistical independence. This double-counts the exact same particle-related biological risk.

The Impossibility of the Back-Cast



Catastrophic Variance

Using a population-average annual apoB slope to reconstruct an individual's unmeasured teenage history generates catastrophic regression-to-the-mean errors.

Life Event Distortion

Real individual trajectories are violently altered by hidden life events: weight changes, diabetes onset, menopause, previously abandoned therapies, and thyroid disease.

Mathematical Reality

A single reconstructed central estimate from midlife back to youth is mathematically invalid. It hides massive uncertainty behind a fake point estimate.

Boundary Conditions: The Rules of ApoB-Years

What It IS Today (Allowed)

- A descriptive research metric of accumulated exposure.
- An integral calculated over a distinctly defined, known time window.
- Computed solely from serial, physically measured laboratory data.
- A visualizer of biological truth for physician context.

What It IS NOT Today (Forbidden)

- An individual event-risk multiplier or prognostic score.
- A lifetime back-cast guessed from a single midlife snapshot.
- An imputed population-average value blended with measured data.
- A clinical threshold carrying recommended pharmaceutical prescription actions.

The Guideline Trajectory (2026 ACC/AHA)

Major 2026 updates:

- Replaces Pooled Cohort Equations with PREVENT-ASCVD (a lifetime-oriented framing).
- Expands selective apoB measurement, particularly for triglycerides >200 mg/dL, diabetes, or achieved LDL-C <70 mg/dL.
- Central framing relies on early intervention to reduce prolonged exposure.



The Crucial Distinction:

The guidelines definitively support the biological concept of early intervention to reduce prolonged exposure. However, they do NOT endorse or validate apoB-years arithmetic, historical back-casting, or cumulative exposure-based treatment thresholds.

The Validation Program: From Concept to Clinical Instrument

Tier 4: Prospective Intervention

Randomized registry deployment comparing exposure-guided versus guideline-goal-guided management with hard event endpoints.

Tier 3: Anatomical Anchoring

Regress serial CCTA plaque volume against apoB-years to replace hypothesized milestones with actual, evidence-based anatomical thresholds.

Tier 2: Back-ost Validation

Compute in cohorts (CARDIA, MESA, UK Biobank) using spline-based mixed models to prrads and retrospective estimation is mathematically viable.



Tier 3: Anatomical Anchoring

Regress serial CCTA plaque volume against apoB-years to replace hypothesized milestones with actual, evidence-based anatomical thresholds.

Tier 2: Back-cast Validation

Compute back-cast estimates against true adolescent measurements to define empirical error bands and prove if retrospective estimation is mathematically viable.

Tier 1: Retrospective Derivation

Compute in cohorts (CARDIA, MESA, UK Biobank) using spline-based mixed models to establish baseline discrimination and calibration against current-value models.

The Dual Truth of Cumulative Exposure



The Reality

Atherosclerosis is irrefutably a disease of cumulative, integrated particle exposure. Our current cross-sectional snapshot paradigm is structurally blind to this, especially in insulin-resistant patients.

The Restraint

We cannot cheat the math. Publishing unvalidated coefficients, exponentiating hazard ratios, and blindly back-casting lifetimes does not fix the clinical paradigm—it compromises it.

The Path Forward

ApoB-years represents the absolute truth of atherogenesis. It is now a candidate metric requiring rigorous derivation, empirical calibration, and external validation before it can dictate patient care.